Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many safety/vaccine-related statements align with the label (notably live vaccine avoidance and TB evaluation), but several mechanistic/immune-system and wide-ranging reactivation/monitoring claims are unsupported or overextended beyond the provided labeling excerpts (e.g., TNF blocker/TNF reduction; numerous reactivation categories not supported).
Category Scores
Accurate Statements
Cosentyx is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported in 1 INDICATIONS AND USAGE (1.1–1.3).
Live vaccines should be avoided during Cosentyx treatment.
Supported in 5 WARNINGS AND PRECAUTIONS (5.7 Immunizations): Avoid use of live vaccines in patients treated with COSENTYX.
Live vaccines can cause severe infections in patients with weakened immune systems.
Consistent with 5.7 Immunizations and overall infection risk framing in 5.1, though the excerpt provided does not state the exact causal phrasing.
TB testing should be performed before starting Cosentyx treatment.
Supported by 2.1 Testing and Procedures Prior to Treatment Initiation and 5.3: Evaluate patients for active or latent TB prior to initiation.
Patients with a history of tuberculosis (TB) should be closely monitored for signs of TB reactivation during Cosentyx treatment.
Supported by 5.3: Monitor patients closely for TB.
Patients with latent TB infection should be treated if necessary before starting Cosentyx treatment.
Supported by 2.1: Initiate treatment of latent TB prior to initiation; and 5.3.
Unsupported Statements
Cosentyx is a tumor necrosis factor (TNF) blocker.
Label excerpt provided describes secukinumab as an IL-17A antagonist (11 DESCRIPTION; 12.1 Mechanism of Action). No TNF-blocking claim is supported.
Cosentyx works by reducing the production of TNF, a protein that contributes to inflammation and joint damage.
No TNF-reduction mechanism is supported by the provided label excerpts; label describes IL-17A antagonism (12.1; 11 DESCRIPTION).
Cosentyx can weaken the immune system, making patients more susceptible to infections.
While 5.1 states increased risk of infections, the specific phrasing about weakening the immune system is not directly supported in the provided excerpts.
Examples of live vaccines that should be avoided during Cosentyx treatment include MMR, varicella (chickenpox), and oral poliovirus.
The provided 5.7 Immunizations excerpt does not list specific live vaccines; not supported by supplied label text.
Inactivated vaccines can be administered during Cosentyx treatment.
The provided excerpts only state to avoid live vaccines (5.7); they do not explicitly state inactivated vaccines may be administered.
A best vaccination schedule should be determined by consulting a healthcare provider.
The label excerpt states complete age-appropriate vaccinations prior to initiation and avoid live vaccines, but does not support advice to determine the schedule with a provider as written.
Certain immunosuppressants can interact with Cosentyx and increase the risk of infections.
The provided drug interaction excerpt (7) is limited to CYP450 substrate considerations; no explicit immunosuppressant interaction statement is supported.
Patients taking concomitant medications should consult a healthcare provider to determine the best vaccination schedule.
The label excerpt does not support this specific counseling statement.
Patients with a history of hepatitis B should be closely monitored for signs of hepatitis B reactivation during Cosentyx treatment.
No hepatitis B reactivation monitoring/testing/treatment content appears in the provided label excerpts.
Hepatitis B testing should be performed before starting Cosentyx treatment.
No hepatitis B testing guidance appears in the provided label excerpts.
Patients should be treated for hepatitis B if necessary before or during Cosentyx treatment.
No hepatitis B treatment guidance appears in the provided label excerpts.
Patients with a history of infections should be closely monitored for signs of reactivation during Cosentyx treatment.
The provided label excerpts emphasize infection risk (5.1) and TB monitoring (5.3) but do not support broad 'reactivation' monitoring across all prior infections.
Patients should be treated promptly if signs of infection occur during Cosentyx treatment.
The label excerpt does not include this specific instruction.
Patients with a history of cancer should be closely monitored for signs of reactivation during Cosentyx treatment.
No cancer-related reactivation monitoring appears in the provided label excerpts.
Patients should be treated promptly if signs of cancer occur during Cosentyx treatment.
No cancer-related guidance appears in the provided label excerpts.
Patients with a history of autoimmune disorders should be closely monitored for signs of reactivation during Cosentyx treatment.
No autoimmune-disorder reactivation monitoring appears in the provided label excerpts.
Patients should be treated promptly if signs of autoimmune disorders occur during Cosentyx treatment.
No autoimmune-disorder guidance appears in the provided label excerpts.
Patients with a history of organ transplant should be closely monitored for signs of rejection during Cosentyx treatment.
No organ transplant/rejection monitoring appears in the provided label excerpts.
Patients should be treated promptly if signs of rejection occur during Cosentyx treatment.
No rejection-related guidance appears in the provided label excerpts.
Patients with a history of HIV/AIDS should be closely monitored for signs of reactivation during Cosentyx treatment.
No HIV/AIDS reactivation monitoring appears in the provided label excerpts.
Patients should be treated promptly if signs of HIV/AIDS occur during Cosentyx treatment.
No HIV/AIDS guidance appears in the provided label excerpts.
Patients with a history of chronic viral hepatitis should be closely monitored for signs of reactivation during Cosentyx treatment.
No chronic viral hepatitis reactivation monitoring appears in the provided label excerpts.
Patients should be treated promptly if signs of chronic viral hepatitis occur during Cosentyx treatment.
No chronic viral hepatitis guidance appears in the provided label excerpts.
Contradictions
High
AI Statement
Cosentyx is a tumor necrosis factor (TNF) blocker.
Label Reference
Label description/mechanism: COSENTYX is an IL-17A antagonist (11 DESCRIPTION; 12.1 Mechanism of Action).
High
AI Statement
Cosentyx works by reducing the production of TNF, a protein that contributes to inflammation and joint damage.
Label Reference
Label description/mechanism: secukinumab selectively binds IL-17A (12.1) rather than TNF.
Important Omissions
No dosage and administration details (e.g., loading vs maintenance, route specifics, self-administration guidance for adults vs pediatric caregiver administration) were evaluated/provided in the AI response list.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Multiple statements are inconsistent with the label mechanism (TNF blocker/TNF reduction), and several infection/vaccination and reactivation-monitoring statements are unsupported by the supplied label excerpts, which could mislead clinical interpretation beyond labeled precautions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Mechanism-of-action inaccuracies (TNF blocker/TNF reduction) and multiple unsupported or overly broad monitoring/treatment and vaccine specifics not present in the provided label excerpts.
Suggested Improvement
Replace TNF-related statements with IL-17A mechanism per label (IL-17A antagonist). Limit immunization guidance to what the label excerpt supports (avoid live vaccines; complete age-appropriate vaccinations prior to initiation). Remove or qualify hepatitis B/cancer/HIV/autoimmune/transplant 'reactivation' monitoring claims unless supported by the specific label sections not provided.